Physician profile
Joel Gellman
NPI 1508855339
$192,658.98
in general payments reported to CMS, 2019-2025
19 companies · $3,035 in 2025
The $3,035 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126K · 2020: $39K · 2021: $15K · 2022: $2,997 · 2023: $2,018 · 2024: $4,812 · 2025: $3,035.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,700 · Food and Beverage: $2,164 · Consulting Fee: $2,000 · Travel and Lodging: $866 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,700.00 |
| Food and Beverage | $2,164.34 |
| Consulting Fee | $2,000.00 |
| Travel and Lodging | $866.29 |
| Education | $133.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $109,736.08 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $52,304.99 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $25,670.48 | 2020-2025 | Farxiga, Lokelma |
| Agepha Pharma Fz LLC | $2,052.82 | 2024 | Lodoco |
| Janssen Research & Development, LLC | $1,001.48 | 2023 | |
| Boston Scientific Corporation | $375.37 | 2021-2023 | Vigilant X4 Crt-D |
| Edwards Lifesciences Corporation | $333.41 | 2023-2025 | |
| Medtronic, INC. | $290.60 | 2021-2025 | Cobalt Dr Mri Surescan |
| Abbott Laboratories | $192.11 | 2023-2025 | Navitor, Aveir |
| Astellas Pharma US INC | $147.98 | 2019-2021 | |
| United Therapeutics Corporation | $125.00 | 2025 | |
| Medtronic Vascular, INC. | $97.68 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.19 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $79.99 | 2024 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.18 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.59 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $28.54 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.79 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $21.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Gellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.